P C Albertsen

Summary

Affiliation: University of Connecticut Health Center
Country: USA

Publications

  1. ncbi request reprint Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist
    Peter C Albertsen
    University of Connecticut Health Center, Farmington, CT, USA Electronic address
    Eur Urol 65:565-73. 2014
  2. pmc What is the risk posed by prostate cancer?
    Peter C Albertsen
    University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    J Natl Cancer Inst Monogr 2012:169-74. 2012
  3. doi request reprint Treatment of localized prostate cancer: when is active surveillance appropriate?
    Peter C Albertsen
    Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
    Nat Rev Clin Oncol 7:394-400. 2010
  4. doi request reprint The face of high risk prostate cancer
    Peter C Albertsen
    Division of Urology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    World J Urol 26:205-10. 2008
  5. ncbi request reprint Lower urinary tract symptoms in the older male
    Kisseng Hsieh
    Division of Urology, University of Connecticut Health Center, MC 3955, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    Conn Med 67:487-90. 2003
  6. ncbi request reprint Prostate cancer and the Will Rogers phenomenon
    Peter C Albertsen
    University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    J Natl Cancer Inst 97:1248-53. 2005
  7. ncbi request reprint Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation
    Peter C Albertsen
    University of Connecticut Health Center, Farmington, Connecticut 06030 3955, USA
    J Urol 171:2221-5. 2004
  8. ncbi request reprint Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?
    Peter C Albertsen
    Department of Surgery, University of Connecticut Health Center, Farmington, 06030 3955, USA
    Acta Oncol 44:255-64. 2005
  9. ncbi request reprint Prostate-specific antigen: how to advise patients as the screening debate continues
    Peter C Albertsen
    Department of Surgery Urology, University of Connecticut Health Center, Farmington, CT 06030 3955, USA
    Cleve Clin J Med 72:521-7. 2005
  10. ncbi request reprint What is the value of screening for prostate cancer in the US?
    Peter C Albertsen
    Department of Surgery Urology, University of Connecticut Health Center, Farmington, CT 06030 3955, USA
    Nat Clin Pract Oncol 2:536-7. 2005

Research Grants

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist
    Peter C Albertsen
    University of Connecticut Health Center, Farmington, CT, USA Electronic address
    Eur Urol 65:565-73. 2014
    ..Androgen deprivation therapy (ADT) is associated with increased cardiovascular morbidity...
  2. pmc What is the risk posed by prostate cancer?
    Peter C Albertsen
    University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    J Natl Cancer Inst Monogr 2012:169-74. 2012
    ..PSA can estimate tumor volume, but poorly differentiated disease may not produce much PSA. We are unable to predict accurately the risk posed by a specific prostate cancer...
  3. doi request reprint Treatment of localized prostate cancer: when is active surveillance appropriate?
    Peter C Albertsen
    Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
    Nat Rev Clin Oncol 7:394-400. 2010
    ..For men harboring tumors with a Gleason score >7, data from two recently reported Swedish trials suggest lower prostate cancer-related mortality for those men receiving either surgery or radiation...
  4. doi request reprint The face of high risk prostate cancer
    Peter C Albertsen
    Division of Urology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    World J Urol 26:205-10. 2008
    ..To define high risk prostate cancer using prostate cancer specific mortality as the key outcome metric...
  5. ncbi request reprint Lower urinary tract symptoms in the older male
    Kisseng Hsieh
    Division of Urology, University of Connecticut Health Center, MC 3955, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    Conn Med 67:487-90. 2003
    ..These combined with a variety of pharmacologic agents (antispasmodics, alpha-antagonists, 5 alpha reductase inhibitors) offer great potential for improving the quality of life of individuals with LUTS...
  6. ncbi request reprint Prostate cancer and the Will Rogers phenomenon
    Peter C Albertsen
    University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    J Natl Cancer Inst 97:1248-53. 2005
    ..To determine whether this decline is in part a result of Gleason score reclassification during the same time period, we documented the potential impact of reclassification between 1992 and 2002 on clinical outcomes...
  7. ncbi request reprint Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation
    Peter C Albertsen
    University of Connecticut Health Center, Farmington, Connecticut 06030 3955, USA
    J Urol 171:2221-5. 2004
    ..This study documents patterns of PSA recurrence after surgery or radiation to treat localized prostate cancer and quantifies the extent to which an increasing PSA predicts death from prostate cancer...
  8. ncbi request reprint Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?
    Peter C Albertsen
    Department of Surgery, University of Connecticut Health Center, Farmington, 06030 3955, USA
    Acta Oncol 44:255-64. 2005
    ..The European screening trial and the PLCO trial in the US will hopefully provide some insights into the value of population-based testing...
  9. ncbi request reprint Prostate-specific antigen: how to advise patients as the screening debate continues
    Peter C Albertsen
    Department of Surgery Urology, University of Connecticut Health Center, Farmington, CT 06030 3955, USA
    Cleve Clin J Med 72:521-7. 2005
    ..A possible schedule is to test at age 40, age 45, and every 2 to 3 years from age 50 until about age 75...
  10. ncbi request reprint What is the value of screening for prostate cancer in the US?
    Peter C Albertsen
    Department of Surgery Urology, University of Connecticut Health Center, Farmington, CT 06030 3955, USA
    Nat Clin Pract Oncol 2:536-7. 2005
  11. ncbi request reprint Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
    P C Albertsen
    Division of Urology, University of Connecticut Health Center, Farmington 06030 3955, USA
    JAMA 280:975-80. 1998
    ..The appropriate therapy for men with localized prostate cancer is uncertain. Until results of clinical trials are available, men and their physicians need guidance...
  12. ncbi request reprint Should men over the age of 65 years receive PSA screening? Argument against
    Peter C Albertsen
    Division of Urology, University of Connecticut Health Center, Farmington, CT 06030, USA
    Nat Clin Pract Urol 5:232-3. 2008
  13. ncbi request reprint PSA and the conservative treatment of early prostate cancer
    Peter C Albertsen
    Division of Urology, University of Connecticut Health Centre, Farmington 06030 3955, USA
    Arch Ital Urol Androl 78:152-3. 2006
    ..Some researchers suggest tracking PSA doubling times as a way of separating those patients with indolent disease from those who are likely to experience progression...
  14. pmc Impact of comorbidity on survival among men with localized prostate cancer
    Peter C Albertsen
    Department of Surgery, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030, USA
    J Clin Oncol 29:1335-41. 2011
    ..To provide patients and clinicians more accurate estimates of comorbidity-specific survival stratified by patient age, tumor stage, and tumor grade...
  15. doi request reprint The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis
    Peter C Albertsen
    Division of Urology, University of Connecticut Health Center, Farmington, Connecticut 06030 3955, USA
    Urology 75:399-405. 2010
    ....
  16. doi request reprint When is active surveillance the appropriate treatment for prostate cancer?
    Peter C Albertsen
    University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
    Acta Oncol 50:120-6. 2011
    ..Furthermore, randomized clinical trials have shown only a modest ten year survival advantage for those men undergoing either surgery or radiation...
  17. ncbi request reprint Should men with low-risk, localized prostate cancer choose active surveillance or undergo a robotic prostatectomy?
    Peter Albertsen
    Division of Urology, University of Connecticut, 263 Farmington Avenue, Farmington, CT 06030, USA
    Curr Urol Rep 9:1-2. 2008
  18. ncbi request reprint 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort
    Peter C Albertsen
    University of Connecticut Health Center, Farmington 06030 3955, and St Francis Hospital and Medical Center, Hartford, Connecticut, USA
    J Urol 177:932-6. 2007
    ....
  19. ncbi request reprint Commentary: occult prostate cancer--imposter or the real deal?
    Peter C Albertsen
    University of Connecticut Health Center, Division of Urology, Urology Office, Farmington, CT 06030 2817, USA
    Int J Epidemiol 36:281-2. 2007
  20. ncbi request reprint 20-year outcomes following conservative management of clinically localized prostate cancer
    Peter C Albertsen
    Division of Urology, University of Connecticut Health Center, Farmington, CT 06030 3955, USA
    JAMA 293:2095-101. 2005
    ..The appropriate therapy for men with clinically localized prostate cancer is uncertain. A recent study suggested an increasing prostate cancer mortality rate for men who are alive more than 15 years following diagnosis...
  21. ncbi request reprint Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation
    Nitya G Chakraborty
    Department of Medicine, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1315, USA
    Cancer Immunol Immunother 52:497-505. 2003
    ....
  22. ncbi request reprint Bicycle riding and its relationship to the development of erectile dysfunction
    John A Taylor
    Division of Urology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    J Urol 172:1028-31. 2004
    ..Insufficient data have left cyclists skeptical of this claim. We explore risk factors within cycling that may put riders at risk for the development of erectile dysfunction (ED)...
  23. ncbi request reprint The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer
    Pamela Taxel
    Division of Endocrinology and Metabolism, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1317, USA
    J Clin Endocrinol Metab 87:4907-13. 2002
    ..We conclude that E(2) inhibits bone resorption in hypogonadal men through a direct skeletal effect that is independent of PTH. Low dose estrogen may be an option for the prevention and/or treatment of bone loss in this population...
  24. doi request reprint Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era
    Barbara Ercole
    Division of Urology, University of Connecticut Health Center, Farmington, Connecticut 06030 3955, USA
    J Urol 180:1336-9; discussion 1340-1. 2008
    ..We gained insights concerning outcomes associated with men who elect active surveillance for the management of localized prostate cancer...
  25. ncbi request reprint The conundrum of prostate cancer
    Peter C Albertsen
    University of Connecticut Health Center, 263 Farmington Avenue, Farmington, Connecticut 06030 3955, USA
    Cancer J 8:432-4. 2002
  26. ncbi request reprint Expression of vascular endothelial growth factor receptors in human prostate cancer
    F A Ferrer
    Department of Surgery, University of Connecticut Health Center, Farmington 06030 3105, USA
    Urology 54:567-72. 1999
    ..Herein, we evaluate the expression of these receptors in ex vivo PCa tissue, benign prostatic hypertrophy (BPH) tissue, and cultured PCa cell lines...
  27. ncbi request reprint Populations at high risk for prostate cancer
    Kisseng Hsieh
    Division of Urology, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    Urol Clin North Am 30:669-76. 2003
    ..Screening men at increased risk of developing prostate cancer appears to be a logical strategy, especially in light of recent reports that suggest a benefit to aggressive treatment...
  28. ncbi request reprint Which results justify the means in prostate cancer treatment?
    Peter C Albertsen
    Department of Surgery, University of Connecticut Health Center, Farmington 06030 3955, USA
    Cancer J 8:30-2. 2002
  29. doi request reprint Use and assessment of PSA in prostate cancer
    Carl K Gjertson
    Division of Urology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3955, USA
    Med Clin North Am 95:191-200. 2011
    ..In this review, the authors discuss the rationale for prostate cancer screening and present the current guidelines for the use of PSA...
  30. doi request reprint Active surveillance for early-stage prostate cancer: review of the current literature
    Marc A Dall'Era
    Department of Urology, University of California at San Francisco Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 1695, USA
    Cancer 112:1650-9. 2008
    ..The best candidates for active surveillance are being defined, as are predictors of active treatment. The psychosocial ramifications of surveillance for prostate cancer can be profound and future needs and unmet goals will be discussed...
  31. pmc Survival following primary androgen deprivation therapy among men with localized prostate cancer
    Grace L Lu-Yao
    Department of Environmental and Occupational Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    JAMA 300:173-81. 2008
    ..Despite a lack of data, increasing numbers of patients are receiving primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation, or conservative management for the treatment of localized prostate cancer...
  32. doi request reprint Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer
    Carine A Bellera
    Department of Clinical Epidemiology and Clinical Research, Institut Bergonie, Regional Comprehensive Cancer Center, Bordeaux, France
    Ann Epidemiol 18:270-82. 2008
    ....
  33. pmc Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut
    Grace Lu-Yao
    HealthStat, Princeton, NJ 08543, USA
    BMJ 325:740. 2002
    ..To determine whether the more intensive screening and treatment for prostate cancer in the Seattle-Puget Sound area in 1987-90 led to lower mortality from prostate cancer than in Connecticut...
  34. pmc Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study
    Simon M Collin
    Department of Social Medicine, University of Bristol, Canynge Hall, Bristol, UK
    Lancet Oncol 9:445-52. 2008
    ..Our aim was to study trends over time in prostate-cancer mortality and incidence in the USA and UK in 1975-2004, and compare these patterns with trends in screening and treatment...
  35. ncbi request reprint Detecting trends in noisy data series: application to biomarker series
    Carine A Bellera
    Department of Clinical Epidemiology and Clinical Research, Institut Bergonie, Regional Comprehensive Cancer Center, Bordeaux, France
    Am J Epidemiol 167:1130-9. 2008
    ..The method is particularly flexible and could be applied to evaluate other rules that purport to accurately detect upturns (downturns) in other noisy data series, including other medical data or other application areas...
  36. ncbi request reprint 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study
    David F Penson
    Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA
    J Urol 173:1701-5. 2005
    ..In this study we assessed temporal changes in urinary and sexual function up to 5 years following radical prostatectomy in a population based cohort...
  37. ncbi request reprint Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer
    Terri Kang Johnson
    University of Southern California Keck School of Medicine, Dept of Preventive Medicine, 1441 Eastlake Ave, Rm 3427A, MC9175, Los Angeles, CA 90089 9175, USA
    J Clin Oncol 22:4193-201. 2004
    ..We investigated racial/ethnic differences in functional outcomes up to 5 years after diagnosis among men with aggressively treated localized prostate cancer...
  38. ncbi request reprint The prostate cancer conundrum
    Peter C Albertsen
    J Natl Cancer Inst 95:930-1. 2003
  39. ncbi request reprint General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study
    David F Penson
    Section of Urology, VA Puget Sound Health Care System and the Department of Urology, University of Washington, Seattle, WA 98108, USA
    J Clin Oncol 21:1147-54. 2003
    ..The goal of this study was to determine the relationship between primary treatment, urinary dysfunction, sexual dysfunction, and general health-related quality of life (HRQOL) in prostate cancer...
  40. ncbi request reprint Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy
    Peter C Albertsen
    J Urol 174:1969-70. 2005
  41. ncbi request reprint Facing erectile dysfunction due to prostate cancer treatment: perspectives of men and their partners
    Peter C Albertsen
    J Urol 174:1969. 2005
  42. ncbi request reprint United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region
    Mary McNaughton Collins
    Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 60:628-33. 2002
    ..To examine whether physicians' views on prostate cancer screening and treatment vary by geographic region in the United States...
  43. ncbi request reprint PSA testing: public policy or private penchant?
    Peter C Albertsen
    JAMA 296:2371-3. 2006
  44. ncbi request reprint Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
    David J Samson
    Technology Evaluation Center, Blue Cross and Blue Shield Association, Washington, DC 20005, USA
    Cancer 95:361-76. 2002
    ..Outcomes of interest included overall, cancer specific, and progression-free survival; time to treatment failure; adverse events; and quality of life...
  45. ncbi request reprint Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis
    Steven B Zeliadt
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Cancer 98:496-503. 2003
    ....
  46. ncbi request reprint Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom
    David F Penson
    University of Washington, Seattle, WA 98106, USA
    Surg Oncol 11:3-11. 2002
    ..Information gathered from large, administrative databases will be helpful when counseling patients regarding their treatments options for localized prostate cancer and in identifying future directions for prostate cancer research...
  47. ncbi request reprint Competing risks for patients with localized prostate cancer
    Jerome Seidenfeld
    J Natl Cancer Inst 99:1498-9. 2007
  48. ncbi request reprint General versus spinal anesthesia in patients undergoing radical retropubic prostatectomy: results of a prospective, randomized study
    Peter C Albertsen
    J Urol 174:931. 2005
  49. ncbi request reprint A charting tool for estimating the PSA doubling time in patients with prostate cancer
    Carine A Bellera
    Int J Radiat Oncol Biol Phys 66:315-6. 2006
  50. ncbi request reprint Outcomes of treatment vs observation of localized prostate cancer in elderly men
    Grace L Lu-Yao
    JAMA 297:1651; author reply 1652-3. 2007
  51. ncbi request reprint Patient outcomes and length of hospital stay after radical prostatectomy for prostate cancer: analysis of hospital episodes statistics for England
    Andrew Judge
    MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Bristol, UK
    BJU Int 100:1040-9. 2007
    ....
  52. ncbi request reprint Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy
    Arnold L Potosky
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD
    J Natl Cancer Inst 94:430-7. 2002
    ..Treatment patterns and quality-of-life outcomes have not been previously reported for a population-based sample of such men...

Research Grants5

  1. COMPARISON OF TREATMENT EFFICACY FOR PROSTATE CANCER
    Peter Albertsen; Fiscal Year: 1999
    ....
  2. COMPARISON OF TREATMENT EFFICACY FOR PROSTATE CANCER
    Peter Albertsen; Fiscal Year: 2000
    ....
  3. COMPARISON OF TREATMENT EFFICACY FOR PROSTATE CANCER
    Peter Albertsen; Fiscal Year: 2001
    ....
  4. COMPARISON OF TREATMENT EFFICACY FOR PROSTATE CANCER
    Peter Albertsen; Fiscal Year: 2002
    ....